#MetaplasticBreastCancer
#CaseReport
56 y/o♀️
5.1 x 4.1 cm right breast mass
lymph nodal➖
Poorly differentiated spindle cell carcinoma
TN, AE1/AE3+, CK8/18+, EMA+, Vim+, Ki67 85%
Neoadjuvant Chemo➡️2.4x1.2x1.7 cm
2 yr disease-free post-mastectomy
#FrontOncol 2026
www.frontiersin.org/journals/onc...
#CaseReport
56 y/o♀️
5.1 x 4.1 cm right breast mass
lymph nodal➖
Poorly differentiated spindle cell carcinoma
TN, AE1/AE3+, CK8/18+, EMA+, Vim+, Ki67 85%
Neoadjuvant Chemo➡️2.4x1.2x1.7 cm
2 yr disease-free post-mastectomy
#FrontOncol 2026
www.frontiersin.org/journals/onc...
September 20, 2026 at 12:17 PM
#MetaplasticBreastCancer
#CaseReport
56 y/o♀️
5.1 x 4.1 cm right breast mass
lymph nodal➖
Poorly differentiated spindle cell carcinoma
TN, AE1/AE3+, CK8/18+, EMA+, Vim+, Ki67 85%
Neoadjuvant Chemo➡️2.4x1.2x1.7 cm
2 yr disease-free post-mastectomy
#FrontOncol 2026
www.frontiersin.org/journals/onc...
#CaseReport
56 y/o♀️
5.1 x 4.1 cm right breast mass
lymph nodal➖
Poorly differentiated spindle cell carcinoma
TN, AE1/AE3+, CK8/18+, EMA+, Vim+, Ki67 85%
Neoadjuvant Chemo➡️2.4x1.2x1.7 cm
2 yr disease-free post-mastectomy
#FrontOncol 2026
www.frontiersin.org/journals/onc...
Pathogenic Germline Variants in Patients With #MetaplasticBreastCancer
N=143
24 with breast cancer genes
17 BRCA1
5 BRCA2
1 PALB2
1 CHEK
Look forward to #WholeGenomeSequencing for MpBC, both germline & somatic🙏
#JAMANetworkOpen 2025
jamanetwork.com/journals/jam...
N=143
24 with breast cancer genes
17 BRCA1
5 BRCA2
1 PALB2
1 CHEK
Look forward to #WholeGenomeSequencing for MpBC, both germline & somatic🙏
#JAMANetworkOpen 2025
jamanetwork.com/journals/jam...
May 4, 2025 at 6:54 PM
Pathogenic Germline Variants in Patients With #MetaplasticBreastCancer
N=143
24 with breast cancer genes
17 BRCA1
5 BRCA2
1 PALB2
1 CHEK
Look forward to #WholeGenomeSequencing for MpBC, both germline & somatic🙏
#JAMANetworkOpen 2025
jamanetwork.com/journals/jam...
N=143
24 with breast cancer genes
17 BRCA1
5 BRCA2
1 PALB2
1 CHEK
Look forward to #WholeGenomeSequencing for MpBC, both germline & somatic🙏
#JAMANetworkOpen 2025
jamanetwork.com/journals/jam...
#MetaplasticBreastCancer
#CaseReport
A 90-gene clinical panel on FFPE section (Ye, J Mol Diagn. 2020), in combination with IHC, to differentiate breast cancers of unknown primary
#cytojournal 2025
cytojournal.com/the-applicat...
#CaseReport
A 90-gene clinical panel on FFPE section (Ye, J Mol Diagn. 2020), in combination with IHC, to differentiate breast cancers of unknown primary
#cytojournal 2025
cytojournal.com/the-applicat...
February 14, 2026 at 7:53 PM
#MetaplasticBreastCancer
#CaseReport
A 90-gene clinical panel on FFPE section (Ye, J Mol Diagn. 2020), in combination with IHC, to differentiate breast cancers of unknown primary
#cytojournal 2025
cytojournal.com/the-applicat...
#CaseReport
A 90-gene clinical panel on FFPE section (Ye, J Mol Diagn. 2020), in combination with IHC, to differentiate breast cancers of unknown primary
#cytojournal 2025
cytojournal.com/the-applicat...
#MetaplasticBreastCancer
#CaseReport
73 y/o♀️
24x18 mm left mass
Spindle-cell carcinoma
Poor margin
TN
Local recurrence 20 mo post-lumpectomy
🫁metastasis 32 mo
Death 40 mo
168-gene panel➡️
3 variants
PIK3R1 p.L573del
RUNX1 p.Y355fs
MYC amplif
#FrontOncol 2026
www.frontiersin.org/journals/onc...
#CaseReport
73 y/o♀️
24x18 mm left mass
Spindle-cell carcinoma
Poor margin
TN
Local recurrence 20 mo post-lumpectomy
🫁metastasis 32 mo
Death 40 mo
168-gene panel➡️
3 variants
PIK3R1 p.L573del
RUNX1 p.Y355fs
MYC amplif
#FrontOncol 2026
www.frontiersin.org/journals/onc...
September 25, 2026 at 12:14 PM
#MetaplasticBreastCancer
#CaseReport
73 y/o♀️
24x18 mm left mass
Spindle-cell carcinoma
Poor margin
TN
Local recurrence 20 mo post-lumpectomy
🫁metastasis 32 mo
Death 40 mo
168-gene panel➡️
3 variants
PIK3R1 p.L573del
RUNX1 p.Y355fs
MYC amplif
#FrontOncol 2026
www.frontiersin.org/journals/onc...
#CaseReport
73 y/o♀️
24x18 mm left mass
Spindle-cell carcinoma
Poor margin
TN
Local recurrence 20 mo post-lumpectomy
🫁metastasis 32 mo
Death 40 mo
168-gene panel➡️
3 variants
PIK3R1 p.L573del
RUNX1 p.Y355fs
MYC amplif
#FrontOncol 2026
www.frontiersin.org/journals/onc...
#MetaplasticBreastCancer Clinico-Pathological analysis
N=67
31% IHC ALDH1+ (cancer stemness), unrelated to histological subtypes
55% PI3K/PTEN mutations
#APMIS 2026
onlinelibrary.wiley.com/doi/10.1111/...
N=67
31% IHC ALDH1+ (cancer stemness), unrelated to histological subtypes
55% PI3K/PTEN mutations
#APMIS 2026
onlinelibrary.wiley.com/doi/10.1111/...
April 29, 2026 at 6:54 PM
#MetaplasticBreastCancer Clinico-Pathological analysis
N=67
31% IHC ALDH1+ (cancer stemness), unrelated to histological subtypes
55% PI3K/PTEN mutations
#APMIS 2026
onlinelibrary.wiley.com/doi/10.1111/...
N=67
31% IHC ALDH1+ (cancer stemness), unrelated to histological subtypes
55% PI3K/PTEN mutations
#APMIS 2026
onlinelibrary.wiley.com/doi/10.1111/...
#MetaplasticBreastCancer #DiffusionWeightedMRI
29🚺
19 squamous + 8 mesenchymal +unclassified histo-type
#ApparentDiffusionCoefficient & tumor size
mesenchymal > squamous
Likely associated with⏬5-y overall/disease-free survival
Dar-Ren Chen lab @plosone.org 2025
journals.plos.org/plosone/arti...
29🚺
19 squamous + 8 mesenchymal +unclassified histo-type
#ApparentDiffusionCoefficient & tumor size
mesenchymal > squamous
Likely associated with⏬5-y overall/disease-free survival
Dar-Ren Chen lab @plosone.org 2025
journals.plos.org/plosone/arti...
May 17, 2025 at 6:55 PM
#MetaplasticBreastCancer #DiffusionWeightedMRI
29🚺
19 squamous + 8 mesenchymal +unclassified histo-type
#ApparentDiffusionCoefficient & tumor size
mesenchymal > squamous
Likely associated with⏬5-y overall/disease-free survival
Dar-Ren Chen lab @plosone.org 2025
journals.plos.org/plosone/arti...
29🚺
19 squamous + 8 mesenchymal +unclassified histo-type
#ApparentDiffusionCoefficient & tumor size
mesenchymal > squamous
Likely associated with⏬5-y overall/disease-free survival
Dar-Ren Chen lab @plosone.org 2025
journals.plos.org/plosone/arti...
#MetaplasticBreastCancer
N=3076 SEER Cohort 2000-2019
Risk factors for Survival
TN MpBC Overall/Breast cancer-specific survival
HR<1
White
Radiotherapy
Chemotherapy (Overall survival only)
HR>1
Age
Tumor stage
Mastectomy
#BMCWomensHealth 2024
bmcwomenshealth.biomedcentral.com/articles/10....
N=3076 SEER Cohort 2000-2019
Risk factors for Survival
TN MpBC Overall/Breast cancer-specific survival
HR<1
White
Radiotherapy
Chemotherapy (Overall survival only)
HR>1
Age
Tumor stage
Mastectomy
#BMCWomensHealth 2024
bmcwomenshealth.biomedcentral.com/articles/10....
February 1, 2025 at 9:16 PM
#MetaplasticBreastCancer
N=3076 SEER Cohort 2000-2019
Risk factors for Survival
TN MpBC Overall/Breast cancer-specific survival
HR<1
White
Radiotherapy
Chemotherapy (Overall survival only)
HR>1
Age
Tumor stage
Mastectomy
#BMCWomensHealth 2024
bmcwomenshealth.biomedcentral.com/articles/10....
N=3076 SEER Cohort 2000-2019
Risk factors for Survival
TN MpBC Overall/Breast cancer-specific survival
HR<1
White
Radiotherapy
Chemotherapy (Overall survival only)
HR>1
Age
Tumor stage
Mastectomy
#BMCWomensHealth 2024
bmcwomenshealth.biomedcentral.com/articles/10....
#MetaplasticBreastCancer
SEER database 2010-2014
1112 MpBC
21321 Tri-neg #BreastCancer
21~24 mo f/up
Chemotherapy-> No benefit
Radiotherapy-> HR=1.5
Compromised survivals of TN vs non-TN MpBC
Breast Cancer Res Treat 2018
link.springer.com/article/10.1...
SEER database 2010-2014
1112 MpBC
21321 Tri-neg #BreastCancer
21~24 mo f/up
Chemotherapy-> No benefit
Radiotherapy-> HR=1.5
Compromised survivals of TN vs non-TN MpBC
Breast Cancer Res Treat 2018
link.springer.com/article/10.1...
December 8, 2024 at 9:38 PM
#MetaplasticBreastCancer
SEER database 2010-2014
1112 MpBC
21321 Tri-neg #BreastCancer
21~24 mo f/up
Chemotherapy-> No benefit
Radiotherapy-> HR=1.5
Compromised survivals of TN vs non-TN MpBC
Breast Cancer Res Treat 2018
link.springer.com/article/10.1...
SEER database 2010-2014
1112 MpBC
21321 Tri-neg #BreastCancer
21~24 mo f/up
Chemotherapy-> No benefit
Radiotherapy-> HR=1.5
Compromised survivals of TN vs non-TN MpBC
Breast Cancer Res Treat 2018
link.springer.com/article/10.1...
#MetaplasticBreastCancer
N=91
21 with immunotherapy
49/58 with genetic testing have no pathogenic mutations!🧐 (On which gene panel?🧐)
61% primary tumors are on left-sided
79% 5-yr overall survival
Baraah Mohamed group #Cureus 2026
www.cureus.com/articles/443...
N=91
21 with immunotherapy
49/58 with genetic testing have no pathogenic mutations!🧐 (On which gene panel?🧐)
61% primary tumors are on left-sided
79% 5-yr overall survival
Baraah Mohamed group #Cureus 2026
www.cureus.com/articles/443...
March 15, 2026 at 12:20 AM
#MetaplasticBreastCancer
N=91
21 with immunotherapy
49/58 with genetic testing have no pathogenic mutations!🧐 (On which gene panel?🧐)
61% primary tumors are on left-sided
79% 5-yr overall survival
Baraah Mohamed group #Cureus 2026
www.cureus.com/articles/443...
N=91
21 with immunotherapy
49/58 with genetic testing have no pathogenic mutations!🧐 (On which gene panel?🧐)
61% primary tumors are on left-sided
79% 5-yr overall survival
Baraah Mohamed group #Cureus 2026
www.cureus.com/articles/443...
#MetaplasticBreastCancer
N=707 N+ (regional lymph node metastasis) cases
SEER database 2000-2015
603 primary
104 secondary
Chemotherapy + radiotherapy
⬇️breast cancer-specific mortality HR=0.71
⬇️non-breast cancer-specific mortality HR=0.32
#FrontOncology 2021
www.frontiersin.org/journals/onc...
N=707 N+ (regional lymph node metastasis) cases
SEER database 2000-2015
603 primary
104 secondary
Chemotherapy + radiotherapy
⬇️breast cancer-specific mortality HR=0.71
⬇️non-breast cancer-specific mortality HR=0.32
#FrontOncology 2021
www.frontiersin.org/journals/onc...
December 17, 2024 at 8:29 PM
#MetaplasticBreastCancer
N=707 N+ (regional lymph node metastasis) cases
SEER database 2000-2015
603 primary
104 secondary
Chemotherapy + radiotherapy
⬇️breast cancer-specific mortality HR=0.71
⬇️non-breast cancer-specific mortality HR=0.32
#FrontOncology 2021
www.frontiersin.org/journals/onc...
N=707 N+ (regional lymph node metastasis) cases
SEER database 2000-2015
603 primary
104 secondary
Chemotherapy + radiotherapy
⬇️breast cancer-specific mortality HR=0.71
⬇️non-breast cancer-specific mortality HR=0.32
#FrontOncology 2021
www.frontiersin.org/journals/onc...
#MetaplasticBreastCancer
Primary👤mammary basal epithelial cell
TGFβ inhibition (A83-01; KO Snai1, Snai2)
⏫Stasis-bypassing into a Pcad+/Ncad+ EMT but⏬metaplastic progenitorness
EZH2 inhibition enforces stasis
#BCRJournal 2024
breast-cancer-research.biomedcentral.com/articles/10....
Primary👤mammary basal epithelial cell
TGFβ inhibition (A83-01; KO Snai1, Snai2)
⏫Stasis-bypassing into a Pcad+/Ncad+ EMT but⏬metaplastic progenitorness
EZH2 inhibition enforces stasis
#BCRJournal 2024
breast-cancer-research.biomedcentral.com/articles/10....
January 10, 2025 at 8:02 PM
#MetaplasticBreastCancer
Primary👤mammary basal epithelial cell
TGFβ inhibition (A83-01; KO Snai1, Snai2)
⏫Stasis-bypassing into a Pcad+/Ncad+ EMT but⏬metaplastic progenitorness
EZH2 inhibition enforces stasis
#BCRJournal 2024
breast-cancer-research.biomedcentral.com/articles/10....
Primary👤mammary basal epithelial cell
TGFβ inhibition (A83-01; KO Snai1, Snai2)
⏫Stasis-bypassing into a Pcad+/Ncad+ EMT but⏬metaplastic progenitorness
EZH2 inhibition enforces stasis
#BCRJournal 2024
breast-cancer-research.biomedcentral.com/articles/10....
#MetaplasticBreastCancer
Non-surgical patient
N=92 + 30
In both cohorts, chemotherapy is associated with improved Overall survival
"Radiotherapy can improve quality of life by alleviating debilitating symptoms" in advanced MpBC
#FrontOncol 2025
www.frontiersin.org/journals/onc...
Non-surgical patient
N=92 + 30
In both cohorts, chemotherapy is associated with improved Overall survival
"Radiotherapy can improve quality of life by alleviating debilitating symptoms" in advanced MpBC
#FrontOncol 2025
www.frontiersin.org/journals/onc...
June 22, 2025 at 9:11 PM
#MetaplasticBreastCancer
Non-surgical patient
N=92 + 30
In both cohorts, chemotherapy is associated with improved Overall survival
"Radiotherapy can improve quality of life by alleviating debilitating symptoms" in advanced MpBC
#FrontOncol 2025
www.frontiersin.org/journals/onc...
Non-surgical patient
N=92 + 30
In both cohorts, chemotherapy is associated with improved Overall survival
"Radiotherapy can improve quality of life by alleviating debilitating symptoms" in advanced MpBC
#FrontOncol 2025
www.frontiersin.org/journals/onc...
#MetaplasticBreastCancer
Re-analysis of scRNAseq (CellxGENE)▶️
A small population (7%, 170/3274 cells) of malignant MpBC cells with a hybrid epithelial-phyllodes signature
Love to see IHC validation & spatial omics🧐
#Pharmaceut_MDPI 2026
www.mdpi.com/1424-8247/19...
Re-analysis of scRNAseq (CellxGENE)▶️
A small population (7%, 170/3274 cells) of malignant MpBC cells with a hybrid epithelial-phyllodes signature
Love to see IHC validation & spatial omics🧐
#Pharmaceut_MDPI 2026
www.mdpi.com/1424-8247/19...
March 11, 2026 at 7:07 PM
#MetaplasticBreastCancer
Re-analysis of scRNAseq (CellxGENE)▶️
A small population (7%, 170/3274 cells) of malignant MpBC cells with a hybrid epithelial-phyllodes signature
Love to see IHC validation & spatial omics🧐
#Pharmaceut_MDPI 2026
www.mdpi.com/1424-8247/19...
Re-analysis of scRNAseq (CellxGENE)▶️
A small population (7%, 170/3274 cells) of malignant MpBC cells with a hybrid epithelial-phyllodes signature
Love to see IHC validation & spatial omics🧐
#Pharmaceut_MDPI 2026
www.mdpi.com/1424-8247/19...
#MetaplasticBreastCancer
#CaseReport
52 y/o
5.9 cm left breast mass
TN, AE1/3+, CK5/6+, p63+, MDM2+, CDK4+, PD-L1+
cT3N0M0 stage IIb
Sternal+Lung metastasis
No progression in 30 mo since KEYNOTE-355/Pembrolizumab
🥸Transient lesion growth by 1 mo
#AmJCaseRep 2026
amjcaserep.com/abstract/ind...
#CaseReport
52 y/o
5.9 cm left breast mass
TN, AE1/3+, CK5/6+, p63+, MDM2+, CDK4+, PD-L1+
cT3N0M0 stage IIb
Sternal+Lung metastasis
No progression in 30 mo since KEYNOTE-355/Pembrolizumab
🥸Transient lesion growth by 1 mo
#AmJCaseRep 2026
amjcaserep.com/abstract/ind...
May 18, 2026 at 7:02 PM
#MetaplasticBreastCancer
#CaseReport
52 y/o
5.9 cm left breast mass
TN, AE1/3+, CK5/6+, p63+, MDM2+, CDK4+, PD-L1+
cT3N0M0 stage IIb
Sternal+Lung metastasis
No progression in 30 mo since KEYNOTE-355/Pembrolizumab
🥸Transient lesion growth by 1 mo
#AmJCaseRep 2026
amjcaserep.com/abstract/ind...
#CaseReport
52 y/o
5.9 cm left breast mass
TN, AE1/3+, CK5/6+, p63+, MDM2+, CDK4+, PD-L1+
cT3N0M0 stage IIb
Sternal+Lung metastasis
No progression in 30 mo since KEYNOTE-355/Pembrolizumab
🥸Transient lesion growth by 1 mo
#AmJCaseRep 2026
amjcaserep.com/abstract/ind...
#MetaplasticBreastCancer
N=48
PD-L1 Combined (tumor+immune cell) Positive Score ≥1
👉✅73% subjects
👉High distal metastasis
👉Not affecting survival
Low Overall Survival
👉High TILs
👉Histo Mesenchymal subtype
👉Lymphovascular invasion
👉Perineural invasion
#Medicina 2026
www.mdpi.com/1648-9144/62...
N=48
PD-L1 Combined (tumor+immune cell) Positive Score ≥1
👉✅73% subjects
👉High distal metastasis
👉Not affecting survival
Low Overall Survival
👉High TILs
👉Histo Mesenchymal subtype
👉Lymphovascular invasion
👉Perineural invasion
#Medicina 2026
www.mdpi.com/1648-9144/62...
May 9, 2026 at 8:08 PM
#MetaplasticBreastCancer
N=48
PD-L1 Combined (tumor+immune cell) Positive Score ≥1
👉✅73% subjects
👉High distal metastasis
👉Not affecting survival
Low Overall Survival
👉High TILs
👉Histo Mesenchymal subtype
👉Lymphovascular invasion
👉Perineural invasion
#Medicina 2026
www.mdpi.com/1648-9144/62...
N=48
PD-L1 Combined (tumor+immune cell) Positive Score ≥1
👉✅73% subjects
👉High distal metastasis
👉Not affecting survival
Low Overall Survival
👉High TILs
👉Histo Mesenchymal subtype
👉Lymphovascular invasion
👉Perineural invasion
#Medicina 2026
www.mdpi.com/1648-9144/62...
#MetaplasticBreastCancer
#CaseReport
51 y/o
1.2 × 1.0 × 0.9 cm
pT1cN0M0
Heterologous mesenchymal differentiation➡️
95% Osteoid matrix
+Osteoclast-like multinucleated giant cells
+DCIS component
BRCA2 c.9676del
#Reports_MDPI 2026
www.mdpi.com/2571-841X/9/...
#CaseReport
51 y/o
1.2 × 1.0 × 0.9 cm
pT1cN0M0
Heterologous mesenchymal differentiation➡️
95% Osteoid matrix
+Osteoclast-like multinucleated giant cells
+DCIS component
BRCA2 c.9676del
#Reports_MDPI 2026
www.mdpi.com/2571-841X/9/...
August 31, 2026 at 12:38 PM
#MetaplasticBreastCancer
#CaseReport
51 y/o
1.2 × 1.0 × 0.9 cm
pT1cN0M0
Heterologous mesenchymal differentiation➡️
95% Osteoid matrix
+Osteoclast-like multinucleated giant cells
+DCIS component
BRCA2 c.9676del
#Reports_MDPI 2026
www.mdpi.com/2571-841X/9/...
#CaseReport
51 y/o
1.2 × 1.0 × 0.9 cm
pT1cN0M0
Heterologous mesenchymal differentiation➡️
95% Osteoid matrix
+Osteoclast-like multinucleated giant cells
+DCIS component
BRCA2 c.9676del
#Reports_MDPI 2026
www.mdpi.com/2571-841X/9/...
#MetaplasticBreastCancer
#CowdenSyndrome PTEN
#CaseReport
A compound case with bilateral breast tumors
24.4 x15.5 cm
15 x15 cm
TN
node+
+recurring left chest wall lesion 5.2 ×4.5 cm
+multi-organ lesions
TAS-117 pan-Akti
All lesions stabilized in 3.8 y
#BJCRep 2026
www.nature.com/articles/s44...
#CowdenSyndrome PTEN
#CaseReport
A compound case with bilateral breast tumors
24.4 x15.5 cm
15 x15 cm
TN
node+
+recurring left chest wall lesion 5.2 ×4.5 cm
+multi-organ lesions
TAS-117 pan-Akti
All lesions stabilized in 3.8 y
#BJCRep 2026
www.nature.com/articles/s44...
May 2, 2026 at 7:46 PM
#MetaplasticBreastCancer
#CowdenSyndrome PTEN
#CaseReport
A compound case with bilateral breast tumors
24.4 x15.5 cm
15 x15 cm
TN
node+
+recurring left chest wall lesion 5.2 ×4.5 cm
+multi-organ lesions
TAS-117 pan-Akti
All lesions stabilized in 3.8 y
#BJCRep 2026
www.nature.com/articles/s44...
#CowdenSyndrome PTEN
#CaseReport
A compound case with bilateral breast tumors
24.4 x15.5 cm
15 x15 cm
TN
node+
+recurring left chest wall lesion 5.2 ×4.5 cm
+multi-organ lesions
TAS-117 pan-Akti
All lesions stabilized in 3.8 y
#BJCRep 2026
www.nature.com/articles/s44...
#MetaplasticBreastCancer
Comparing somatic mutational burden of paired primary tumors vs metastasis
N=17 (8 +lymph node metastasis; 1 +distal metastasis)
Predominantly < 10 mutation/Mb
TP53 PIK3CA PTEM MCL1 MYC
No microsatellite instability
#BreastCancer 2026
www.dovepress.com/clonal-dynam...
Comparing somatic mutational burden of paired primary tumors vs metastasis
N=17 (8 +lymph node metastasis; 1 +distal metastasis)
Predominantly < 10 mutation/Mb
TP53 PIK3CA PTEM MCL1 MYC
No microsatellite instability
#BreastCancer 2026
www.dovepress.com/clonal-dynam...
March 22, 2026 at 7:11 PM
#MetaplasticBreastCancer
Comparing somatic mutational burden of paired primary tumors vs metastasis
N=17 (8 +lymph node metastasis; 1 +distal metastasis)
Predominantly < 10 mutation/Mb
TP53 PIK3CA PTEM MCL1 MYC
No microsatellite instability
#BreastCancer 2026
www.dovepress.com/clonal-dynam...
Comparing somatic mutational burden of paired primary tumors vs metastasis
N=17 (8 +lymph node metastasis; 1 +distal metastasis)
Predominantly < 10 mutation/Mb
TP53 PIK3CA PTEM MCL1 MYC
No microsatellite instability
#BreastCancer 2026
www.dovepress.com/clonal-dynam...
#MetaplasticBreastCancer
#CaseReport
N=7 MpBC with heterogeneous mesenchymal & matrix components
c-MYC amplification (ISH) in 6/7 cases
#AnnDiagnPathol 2026
www.sciencedirect.com/science/arti...
#CaseReport
N=7 MpBC with heterogeneous mesenchymal & matrix components
c-MYC amplification (ISH) in 6/7 cases
#AnnDiagnPathol 2026
www.sciencedirect.com/science/arti...
March 30, 2026 at 7:42 PM
#MetaplasticBreastCancer
#CaseReport
N=7 MpBC with heterogeneous mesenchymal & matrix components
c-MYC amplification (ISH) in 6/7 cases
#AnnDiagnPathol 2026
www.sciencedirect.com/science/arti...
#CaseReport
N=7 MpBC with heterogeneous mesenchymal & matrix components
c-MYC amplification (ISH) in 6/7 cases
#AnnDiagnPathol 2026
www.sciencedirect.com/science/arti...
#MetaplasticBreastCancer
A CatBoost model predicts 5-y/o survival MpBC with AUC=0.810
Outperforming RF XGBoost KNN SVM LightGBM
Variable contributions
T stage > N stage > Age > ChemoT > surgery type > M stage > Histo subtype > RadioT
Breast 2024
www.thebreastonline.com/article/S096...
A CatBoost model predicts 5-y/o survival MpBC with AUC=0.810
Outperforming RF XGBoost KNN SVM LightGBM
Variable contributions
T stage > N stage > Age > ChemoT > surgery type > M stage > Histo subtype > RadioT
Breast 2024
www.thebreastonline.com/article/S096...
January 17, 2025 at 7:58 PM
#MetaplasticBreastCancer
A CatBoost model predicts 5-y/o survival MpBC with AUC=0.810
Outperforming RF XGBoost KNN SVM LightGBM
Variable contributions
T stage > N stage > Age > ChemoT > surgery type > M stage > Histo subtype > RadioT
Breast 2024
www.thebreastonline.com/article/S096...
A CatBoost model predicts 5-y/o survival MpBC with AUC=0.810
Outperforming RF XGBoost KNN SVM LightGBM
Variable contributions
T stage > N stage > Age > ChemoT > surgery type > M stage > Histo subtype > RadioT
Breast 2024
www.thebreastonline.com/article/S096...
Nation-wide Histology Database of >830k invasive primary #BreastCancer!!👹
2250 cases of #MetaplasticBreastCancer🔥
NHS England
18–89 y/o
1988-2016
#JPatholClinRes 2025
pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/...
2250 cases of #MetaplasticBreastCancer🔥
NHS England
18–89 y/o
1988-2016
#JPatholClinRes 2025
pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/...
December 2, 2025 at 7:56 PM
Nation-wide Histology Database of >830k invasive primary #BreastCancer!!👹
2250 cases of #MetaplasticBreastCancer🔥
NHS England
18–89 y/o
1988-2016
#JPatholClinRes 2025
pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/...
2250 cases of #MetaplasticBreastCancer🔥
NHS England
18–89 y/o
1988-2016
#JPatholClinRes 2025
pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/...
#MetaplasticBreastCancer
SEER database n=2260 N0M0 (No lymph node involvement; No metastasis)
Independent prognostic factor for worse breast cancer-specific or overall survival
⬆️Age at diagnosis
Undifferentiated tumor
⬆️Tumor size
No Chemo/Radiotherapy
#Medicine 2026
www.ovid.com/jnls/md-jour...
SEER database n=2260 N0M0 (No lymph node involvement; No metastasis)
Independent prognostic factor for worse breast cancer-specific or overall survival
⬆️Age at diagnosis
Undifferentiated tumor
⬆️Tumor size
No Chemo/Radiotherapy
#Medicine 2026
www.ovid.com/jnls/md-jour...
August 26, 2026 at 12:10 PM
#MetaplasticBreastCancer
SEER database n=2260 N0M0 (No lymph node involvement; No metastasis)
Independent prognostic factor for worse breast cancer-specific or overall survival
⬆️Age at diagnosis
Undifferentiated tumor
⬆️Tumor size
No Chemo/Radiotherapy
#Medicine 2026
www.ovid.com/jnls/md-jour...
SEER database n=2260 N0M0 (No lymph node involvement; No metastasis)
Independent prognostic factor for worse breast cancer-specific or overall survival
⬆️Age at diagnosis
Undifferentiated tumor
⬆️Tumor size
No Chemo/Radiotherapy
#Medicine 2026
www.ovid.com/jnls/md-jour...
#MetaplasticBreastCancer
n=44🇬🇷
YAP/TAZ immunoreactivity in MpBC
Not corr. CTGF CCND1
Not corr. Histological/Molecular subtype
Not corr. Disease-free survival
Marginal corr. Overall survival
Chemo➡️⏫survival
Recurrence➡️⏬ survival HR>100😨
#CurrIssuesMolBiol 2025
www.mdpi.com/1467-3045/47...
n=44🇬🇷
YAP/TAZ immunoreactivity in MpBC
Not corr. CTGF CCND1
Not corr. Histological/Molecular subtype
Not corr. Disease-free survival
Marginal corr. Overall survival
Chemo➡️⏫survival
Recurrence➡️⏬ survival HR>100😨
#CurrIssuesMolBiol 2025
www.mdpi.com/1467-3045/47...
February 9, 2026 at 8:13 PM
#MetaplasticBreastCancer
n=44🇬🇷
YAP/TAZ immunoreactivity in MpBC
Not corr. CTGF CCND1
Not corr. Histological/Molecular subtype
Not corr. Disease-free survival
Marginal corr. Overall survival
Chemo➡️⏫survival
Recurrence➡️⏬ survival HR>100😨
#CurrIssuesMolBiol 2025
www.mdpi.com/1467-3045/47...
n=44🇬🇷
YAP/TAZ immunoreactivity in MpBC
Not corr. CTGF CCND1
Not corr. Histological/Molecular subtype
Not corr. Disease-free survival
Marginal corr. Overall survival
Chemo➡️⏫survival
Recurrence➡️⏬ survival HR>100😨
#CurrIssuesMolBiol 2025
www.mdpi.com/1467-3045/47...
#MetaplasticBreastCancer
#CaseReport
Immunotherapy-refractory
47 y/o
Rapid growth
40 mm cT2N0M0 stage IIA➡️80 mm cT4bN1M0 stage IIIB in 2-wk Keynote-522 regimen: pembrolizumab +paclitaxel +carboplatin
No recurrence in 18 mo post-mastectomy
#NagoyaJMedSci 2026
pmc.ncbi.nlm.nih.gov/articles/PMC...
#CaseReport
Immunotherapy-refractory
47 y/o
Rapid growth
40 mm cT2N0M0 stage IIA➡️80 mm cT4bN1M0 stage IIIB in 2-wk Keynote-522 regimen: pembrolizumab +paclitaxel +carboplatin
No recurrence in 18 mo post-mastectomy
#NagoyaJMedSci 2026
pmc.ncbi.nlm.nih.gov/articles/PMC...
May 16, 2026 at 7:00 PM
#MetaplasticBreastCancer
#CaseReport
Immunotherapy-refractory
47 y/o
Rapid growth
40 mm cT2N0M0 stage IIA➡️80 mm cT4bN1M0 stage IIIB in 2-wk Keynote-522 regimen: pembrolizumab +paclitaxel +carboplatin
No recurrence in 18 mo post-mastectomy
#NagoyaJMedSci 2026
pmc.ncbi.nlm.nih.gov/articles/PMC...
#CaseReport
Immunotherapy-refractory
47 y/o
Rapid growth
40 mm cT2N0M0 stage IIA➡️80 mm cT4bN1M0 stage IIIB in 2-wk Keynote-522 regimen: pembrolizumab +paclitaxel +carboplatin
No recurrence in 18 mo post-mastectomy
#NagoyaJMedSci 2026
pmc.ncbi.nlm.nih.gov/articles/PMC...
#MetaplasticBreastcancer Imaging
N=36🇨🇳
Mammography Echo MRI
70% cases exhibit irregular, even spiculated, shape
1/3~1/2 contain calcification
#AcadRadiol 2024
www.sciencedirect.com/science/arti...
N=36🇨🇳
Mammography Echo MRI
70% cases exhibit irregular, even spiculated, shape
1/3~1/2 contain calcification
#AcadRadiol 2024
www.sciencedirect.com/science/arti...
December 23, 2024 at 7:12 PM
#MetaplasticBreastcancer Imaging
N=36🇨🇳
Mammography Echo MRI
70% cases exhibit irregular, even spiculated, shape
1/3~1/2 contain calcification
#AcadRadiol 2024
www.sciencedirect.com/science/arti...
N=36🇨🇳
Mammography Echo MRI
70% cases exhibit irregular, even spiculated, shape
1/3~1/2 contain calcification
#AcadRadiol 2024
www.sciencedirect.com/science/arti...